TROP2

EGP-1; M1S1; GA733-1

TROP2 is a transmembrane glycoprotein that belongs to the GA733 family. Trop2 has several ligands, including claudin-1, claudin-7, and cyclin D1. Trop2 activity requires regulated intramembrane proteolysis (RIP). RIP cleaves Trop2 by TNF-α converting enzyme (TACE), followed by γ-secretase cleavage within the transmembrane domain. TROP2 can activate the ERK1/3-MAPK pathway. TROP2 signals cells to self-renewal, proliferation, invasion, and survival. Trop2 has stem cell-like properties. TROP2 is overexpressed in a variety of human cancers, including breast, cervical, colorectal, esophageal (some types), lung (some types), non-Hodgkin lymphoma, chronic lymphocytic lymphoma (CLL), Rajburkitt's lymphoma, oral squamous cell carcinoma, ovarian, pancreatic, prostate, gastric, thyroid, bladder, and uterine cancers.

References:

[1]. Shvartsur A, et al. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015 Mar;6(3-4):84-105. [Content Brief]

TROP2 Inhibitors (6)

TROP2 Related Products (6):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-132254

Sacituzumab govitecan	Inhibitor	99.13%
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity.

HY-P99045

Sacituzumab	Inhibitor	99.77%
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer.

HY-141598

Datopotamab deruxtecan	Inhibitor	99.54%
Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity.

HY-P99843

Datopotamab	Inhibitor	99.00%
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer.

HY-132254A

Sacituzumab govitecan (solution)	Inhibitor
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity.

HY-164789

Sacituzumab tirumotecan	Inhibitor	99.63%
Sacituzumab tirumotecan (SKB264/MK-2870) is a TROP2 ADC. Sacituzumab tirumotecan can be used for the research of triple-negative breast cancer (TNBC).

Name
Email *

	Sorry, but the email address you supplied was invalid.